Salix Pharmaceuticals Ltd. (SLXP) and Progenics Pharmaceuticals (PGNX) announced the results from a Phase 3 trial Tuesday morning, which evaluated the efficacy and safety of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, non-cancer pain. The trial demonstrated highly statistically significant results for the primary endpoint in two of the three treatment arms when compared to the placebo treatment arm.
Salix Pharmaceuticals gapped open sharply higher Tuesday, but traded in a range for the majority of the session. Shares finished up by 3.71 at $46.94 on above average volume. The stock rose above a 3-week range and set an 11 1/2 month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.